Defendant
4 cases as defendant.
Hatch-Waxman ANDA patent infringement action in the District of New Jersey. The multi-patent Xyrem complaint included US 7,668,730 and also asserted the '059, '988, '182, and '963 patents. The case was resolved short of trial and closed.
Jazz sued Ranbaxy entities in D.N.J. involving the '106 patent. The case was closed and later settled.
One of the consolidated D.N.J. Xyrem ANDA actions against Ranbaxy. A consolidation stipulation recites that this action alleged infringement of a patent list including US 6,780,889; it was consolidated with related Xyrem actions and resolved/terminated in the 2015-2018 window.
Filed after Ranbaxy's June 3, 2014 Paragraph IV notice; settled. The narrative lists this docket and/or 2:14-cv-04467 for the Ranbaxy suit.